Intended for healthcare professionals


HIV/AIDS programmes should focus on improved access

BMJ 2000; 321 doi: (Published 14 October 2000) Cite this as: BMJ 2000;321:963
  1. Alex Manning, general registrar (
  1. Burwell Surgery, Burwell, Cambridgeshire CB5 0AE

    EDITOR—GlaxoWellcome's recent move to reduce the cost of antiretroviral drugs in sub-Saharan Africa,1 although to be applauded, is unlikely to have an impact on most of those infected with or affected by HIV/AIDS in sub-Saharan Africa. The cost of monitoring and treating patients with AIDS with antiretrovirals is high; even an antenatal screening programme creates considerable problems, with extra laboratory and counselling services needed and the risk of a hostile community reaction. Maintaining long term prophylaxis …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription